Back to Search
Start Over
ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
- Source :
- Journal of Antimicrobial Chemotherapy, Journal of Antimicrobial Chemotherapy, 2016, 71 (9), pp.2386--2396. ⟨10.1093/jac/dkw156⟩, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2016, 71 (9), pp.2386--2396. ⟨10.1093/jac/dkw156⟩, Journal of Antimicrobial Chemotherapy, 71, 9, pp. 2386-96, Journal of Antimicrobial Chemotherapy, 71, 2386-96
- Publication Year :
- 2016
- Publisher :
- Oxford University Press, 2016.
-
Abstract
- Item does not contain fulltext The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a meeting to establish evidence-based recommendations for using tests to diagnose Pneumocystis jirovecii pneumonia (PCP) in adult patients with haematological malignancies. Immunofluorescence assays are recommended as the most sensitive microscopic method (recommendation A-II: ). Real-time PCR is recommended for the routine diagnosis of PCP ( A-II: ). Bronchoalveolar lavage (BAL) fluid is recommended as the best specimen as it yields good negative predictive value ( A-II: ). Non-invasive specimens can be suitable alternatives ( B-II: ), acknowledging that PCP cannot be ruled out in case of a negative PCR result ( A-II: ). Detecting beta-d-glucan in serum can contribute to the diagnosis but not the follow-up of PCP ( A-II: ). A negative serum beta-d-glucan result can exclude PCP in a patient at risk ( A-II: ), whereas a positive test result may indicate other fungal infections. Genotyping using multilocus sequence markers can be used to investigate suspected outbreaks ( A-II: ). The routine detection of dihydropteroate synthase mutations in cases of treatment failure is not recommended ( B-II: ) since these mutations do not affect response to high-dose co-trimoxazole. The clinical utility of these diagnostic tests for the early management of PCP should be further assessed in prospective, randomized interventional studies.
- Subjects :
- 0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
030106 microbiology
Dapsone
Pneumocystis carinii
03 medical and health sciences
Immunocompromised Host
0302 clinical medicine
Diagnostic Tests
Internal medicine
medicine
Pneumocistis jirovecii
Humans
Routine
Pharmacology (medical)
030212 general & internal medicine
Intensive care medicine
Pharmacology
Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]
business.industry
Diagnostic Tests, Routine
Pneumocystis
Pneumonia, Pneumocystis
Pneumonia
medicine.disease
Trimethoprim
Transplant Recipients
3. Good health
Fludarabine
Regimen
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
Infectious Diseases
Hematologic Neoplasms
Alemtuzumab
Rituximab
business
Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Pentamidine
medicine.drug
immunocompromised host, pneumonia, Pneumocistis jirovecii
Stem Cell Transplantation
Subjects
Details
- Language :
- English
- ISSN :
- 03057453 and 14602091
- Database :
- OpenAIRE
- Journal :
- Journal of Antimicrobial Chemotherapy, Journal of Antimicrobial Chemotherapy, 2016, 71 (9), pp.2386--2396. ⟨10.1093/jac/dkw156⟩, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2016, 71 (9), pp.2386--2396. ⟨10.1093/jac/dkw156⟩, Journal of Antimicrobial Chemotherapy, 71, 9, pp. 2386-96, Journal of Antimicrobial Chemotherapy, 71, 2386-96
- Accession number :
- edsair.doi.dedup.....fd976587c4452dc4c99f5eff6a7a5a2b